Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma

Authors :: Michael Andersson
Flora E. van Leeuwen
Hans H. Storm
Heikki Joensuu
Magnus Kaijser
Susan A. Smith
Lois B. Travis
Ruth A. Kleinerman
David C. Hodgson
Per Hall
Joseph F. Fraumeni
Ethel S. Gilbert
Frøydis Langmark
Eric J. Holowaty
Charles F. Lynch
Steven L. Simon
Graça M. Dores
Rita E. Weathers
Berthe M.P. Aleman
Eero Pukkala
Tom Børge Johannesen
Marilyn Stovall
Stephanie Lamart
Sophie D. Fosså
Lindsay M. Morton
Leila Vaalavirta
Rochelle E. Curtis
Source :: Haematologica. 99:e193-e196
Publication Year :: 2014
Publisher :: Ferrata Storti Foundation (Haematologica), 2014.
Abstract: Advances in Hodgkin lymphoma (HL) treatment have dramatically improved prognosis, with 5-year relative survival now over 80% in the United States (US) and Europe. However, subsequent malignancies, often occurring as late adverse effects of treatment, are a leading cause of morbidity and mortality

Full Text Access

Tools